株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

新興のバイオテクノロジー - アンチセンスRNAi治療薬市場分析

PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis

発行 GlobalData 商品コード 340300
出版日 ページ情報 英文 124 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
新興のバイオテクノロジー - アンチセンスRNAi治療薬市場分析 PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis
出版日: 2015年09月01日 ページ情報: 英文 124 Pages
概要

当レポートでは、RNA干渉治療分野について調査し、詳細な企業データと企業戦略、市場動向、RNAi治療薬市場の現状と将来的成長牽引因子、競合環境と新興戦略などについて詳細にまとめています。

第1章 目次

第2章 イントロダクション

第3章 アンチセンスRNAi治療概要

  • アンチセンス治療とは
  • RNAiの第二の時代とは

第4章 治験

  • 概要
  • 企業
  • 開発段階
  • 治療分野
  • 適応
  • 治験責任医師

第5章 企業分析

  • 概要
  • パイプラインプロファイル
    • Alnylam Pharmaceuticals
    • Antisense Therapeutics
    • Arrowhead Research Corporation
    • AuraSense Therapeutics
    • BioMarin Pharmaceuticals
    • Dicerna Pharmaceuticals
    • Gene Signal International SA
    • Idera Pharmaceuticals
    • InDex Pharmaceuticals AB
    • Isarna Therapeutics GmbH
    • Isis Pharmaceuticals
    • Miragen Therapeutics
    • Mirna Therapeutics
    • Moderna Therapeutics
    • Mologen AG
    • Oncogenex Pharmaceuticals
    • Quark Pharmaceuticals
    • Regulus Therapeutics
    • RXi Pharmaceuticals
    • Sarepta Therapeutics
    • Silence Therapeutics Plc
    • Sirnaomics
    • Sterna Biologicals GmbH
    • Sylentis SA
    • Tekmira (Arbutus) Pharmaceuticals

第6章 取引環境

  • 概要
  • 種類
    • 合併・買収
    • ライセンシング・提携
    • 資金調達

第7章 戦略的見通し

第8章 付録

図表

目次
Product Code: GDHC015PSR

GlobalData's "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, GlobalData provides an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights into the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of RNAi therapeutics.

Highlights

Key Questions Answered

  • What are the drivers of the RNAi therapy field?
  • Who are the leading companies involved in the development of RNAi therapies?
  • What are the major trends in RNAi clinical trials?
  • What specific therapeutic areas and indications are receiving the most clinical research?
  • What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)?
  • Has investor confidence been restored in the antisense/RNAi therapy field?

Scope

  • This report provides market developments across the RNAi therapy field, including clinical trials, deals, and pipeline investments
  • Investment examined from both industry and financial communities
  • Clinical trials activity examined across phase of development, therapy area, and indication.
  • This report offers a deep dive into the synergies behind partnering and acquisition activities
  • Deals examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action
  • Pipeline profiles of 25 leading biotech companies developing RNAi therapeutics

Reasons to buy

  • Identify the key players in the RNAi market.
  • Analyze and track the strategies that companies are using to strengthen their position in the RNAi therapy field; independent source for due diligence.
  • Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, investment, or takeover.
  • Understand the flow of investment from capital markets into the RNAi therapy field.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Companies Mentioned
  • 2.3. Related Reports

3. Antisense RNAi Therapy Overview

  • 3.1. What is Antisense Therapy?
    • 3.1.1. Mechanisms
  • 3.2. The Second Era of RNAi

4. Clinical Trials

  • 4.1. Overview
  • 4.2. Company
  • 4.3. Phase of Development
  • 4.4. Therapy Area
  • 4.5. Indication
    • 4.5.1. Cardiovascular: Atherosclerosis
    • 4.5.2. CNS: Duchenne Muscular Dystrophy
    • 4.5.3. Infectious Diseases: Hepatitis Infections
  • 4.6. Investigators
    • 4.6.1. Specialty
    • 4.6.2. Region

5. Company Analysis

  • 5.1. Overview
    • 5.1.1. Revenue
    • 5.1.2. R&D Spending
    • 5.1.3. Market Capitalization
  • 5.2. Pipeline Profiles
    • 5.2.1. Alnylam Pharmaceuticals
    • 5.2.2. Antisense Therapeutics
    • 5.2.3. Arrowhead Research Corporation
    • 5.2.4. AuraSense Therapeutics
    • 5.2.5. BioMarin Pharmaceuticals
    • 5.2.6. Dicerna Pharmaceuticals
    • 5.2.7. Gene Signal International SA
    • 5.2.8. Idera Pharmaceuticals
    • 5.2.9. InDex Pharmaceuticals AB
    • 5.2.10. Isarna Therapeutics GmbH
    • 5.2.11. Isis Pharmaceuticals
    • 5.2.12. Miragen Therapeutics
    • 5.2.13. Mirna Therapeutics
    • 5.2.14. Moderna Therapeutics
    • 5.2.15. Mologen AG
    • 5.2.16. Oncogenex Pharmaceuticals
    • 5.2.17. Quark Pharmaceuticals
    • 5.2.18. Regulus Therapeutics
    • 5.2.19. RXi Pharmaceuticals
    • 5.2.20. Sarepta Therapeutics
    • 5.2.21. Silence Therapeutics Plc
    • 5.2.22. Sirnaomics
    • 5.2.23. Sterna Biologicals GmbH
    • 5.2.24. Sylentis SA
    • 5.2.25. Tekmira (Arbutus) Pharmaceuticals

6. Deals Landscape

  • 6.1. Overview
    • 6.1.1. Geography
    • 6.1.2. Entity
    • 6.1.3. Company
    • 6.1.4. Stage
    • 6.1.5. Therapy Area
    • 6.1.6. Indication
    • 6.1.7. Mechanism of Action
  • 6.2. Deal Type
    • 6.2.1. Mergers and Acquisitions
    • 6.2.2. Licensing & Partnerships
    • 6.2.3. Capital Raisings

7. Strategic Outlook

8. Appendix

  • 8.1. Bibliography
  • 8.2. Research Methodology
    • 8.2.1. Coverage
    • 8.2.2. Secondary Research
  • 8.3. About the Author
    • 8.3.1. Adam Dion, Senior Industry Analyst
  • 8.4. About GlobalData
  • 8.5. Disclosure Information
  • 8.6. Disclaimer

List of Tables

  • Table 1: Alnylam Pharmaceuticals, Pipeline Programs, Phase I-III
  • Table 2: Alnylam Pharmaceuticals, Pipeline Programs, Preclinical
  • Table 3: Alnylam Pharmaceuticals, Pipeline Programs, Discovery
  • Table 4: Antisense Therapeutics
  • Table 5: Arrowhead Research Corporation
  • Table 6: AuraSense Therapeutics
  • Table 7: BioMarin Pharmaceuticals
  • Table 8: Dicerna Pharmaceuticals
  • Table 9: Gene Signal International SA
  • Table 10: Idera Pharmaceuticals
  • Table 11: InDex Pharmaceuticals AB
  • Table 12: Isarna Therapeutics GmbH
  • Table 13: Isis Pharmaceuticals, Pipeline Programs, Phase II-III
  • Table 14: Isis Pharmaceuticals, Pipeline Programs, Phase I
  • Table 15: Isis Pharmaceuticals, Pipeline Programs, Preclinical
  • Table 16: Miragen Therapeutics
  • Table 17: Mirna Therapeutics
  • Table 18: Moderna Therapeutics
  • Table 19: Mologen AG
  • Table 20: Oncogenex Pharmaceuticals
  • Table 21: Quark Pharmaceuticals
  • Table 22: Regulus Therapeutics
  • Table 23: RXi Pharmaceuticals
  • Table 24: Sarepta Therapeutics, Pipeline Programs, Preclinical-Phase III
  • Table 25: Sarepta Therapeutics, Pipeline Programs, Discovery
  • Table 26: Silence Therapeutics Plc
  • Table 27: Sirnaomics, Pipeline Programs, Preclinical
  • Table 28: Sterna Biologicals GmbH
  • Table 29: Sylentis SA
  • Table 30: Tekmira Pharmaceuticals, Pipeline Programs, Phase I-II
  • Table 31: Tekmira Pharmaceuticals, Pipeline Programs, Preclinical
  • Table 32: Antisense Therapy, M&A Deals Table Summary, 2010-2015
  • Table 33: Antisense Therapy, Licensing Deals Table Summary, 2010-2015
  • Table 34: Antisense Therapy, Licensing Deals Table Summary, Cont'd, 2010-2015
  • Table 35: Antisense Therapy, Capital Raisings Table Summary, 2012-2015

List of Figures

  • Figure 1: Antisense Therapy Clinical Trials by Top Indications and Phase of Development
  • Figure 2: Antisense Therapy Clinical Trials (>10) by Company
  • Figure 3: Antisense Therapy Clinical Trials (<10) by Company
  • Figure 4: Antisense Therapy Clinical Trials by Company and Phase of Development
  • Figure 5: Antisense Therapy Clinical Trials by Phase of Development, 1996-2015
  • Figure 6: Antisense Therapy Clinical Trials (%) by Phase of Development, 1996-2015
  • Figure 7: Antisense Therapy Clinical Trials by Phase of Development, 2009-2015
  • Figure 8: Antisense Clinical Trials by Therapy Area
  • Figure 9: Antisense Clinical Trials, Percentage (%) by Therapy Area
  • Figure 10: Antisense Clinical Trials by Therapy Area and Phase of Development
  • Figure 11: Antisense Therapy Clinical Trials, Top Indications
  • Figure 12: Antisense Therapy Clinical Trials, Top Indications by Development Phase
  • Figure 13: Antisense Therapy Clinical Trials by Indication, Cardiovascular Disorders
  • Figure 14: Antisense Therapy Clinical Trials by Indication, CNS Disorders
  • Figure 15: Antisense Therapy Clinical Trials by Indication, Infectious Diseases
  • Figure 16: Number of Investigators by Specialty
  • Figure 17: Number of Investigators by Region
  • Figure 18: Antisense Therapy Companies by Revenue ($m), 2014
  • Figure 19: Antisense Therapy Companies by R&D Spending ($m), 2014
  • Figure 20: Antisense Therapy Companies by Market Cap ($m)
  • Figure 21: Antisense Therapy Deals, Total Deals and Deal Values ($m), 2010-2015
  • Figure 22: Antisense Therapy Deals, Deal Type Breakdown ($m), 2010-2015
  • Figure 23: Antisense Therapy Deals, Total Deals and Deal Values ($m) by Region, 2010-2015
  • Figure 24: Antisense Therapy Deals by Region (%), 2010-2015
  • Figure 25: Antisense Therapy Deals by Region, Deal Value ($m), 2010-2015
  • Figure 26: Antisense Therapy Deals by Entity Type, Private vs. Public, 2010-2015
  • Figure 27: Antisense Therapy Deals by Company, 2010-2015
  • Figure 28: Antisense Therapy Deals by Product Stage, 2010-2015
  • Figure 29: Antisense Therapy Deals, Upfront and Milestone Payments ($m), by Product Stage, 2010-2015
  • Figure 30: Antisense Therapy Deals by Product Stage (%), 2010-2015
  • Figure 31: Antisense Therapy Deals by Product Stage, Deal Value ($m), 2010-2015
  • Figure 32: Antisense Therapy Deals, Total Deals and Deal Values ($m) by Therapy Area, 2010-2015
  • Figure 33: Antisense Therapy Deals, Upfront and Milestone Payments ($m), by Therapy Area, 2010-2015
  • Figure 34: Antisense Therapy Deals by Indication, 2010-2015
  • Figure 35: Antisense Therapy Deals by Indication, Cont'd, 2010-2015
  • Figure 36: Antisense Therapy Deals by Mechanism of Action, 2010-2015
  • Figure 37: Antisense Therapy Deals by Deal Type (%), 2010-2015
  • Figure 38: Antisense Therapy, Number of M&A Deals and Deal Values ($m), 2010-2015
  • Figure 39: Antisense Therapy, Number of Licensing Deals and Deal Values ($m), 2010-2015
  • Figure 40: Antisense Therapy, Number of Capital Raisings and Deal Values ($m), 2010-2015
  • Figure 41: Antisense Therapy, Capital Raisings by Company ($m), 2010-2015
  • Figure 42: Antisense Therapy, Capital Raisings by Financial Institution ($m), 2010-2015
Back to Top